TY - JOUR
T1 - Potential therapeutic role of para-aortic lymphadenectomy in node- positive endometrial cancer
AU - Mariani, Andrea
AU - Webb, Maurice J.
AU - Galli, Laura
AU - Podratz, Karl C.
PY - 2000/3
Y1 - 2000/3
N2 - Objective. The aim of this study was to assess the potential therapeutic role of para-aortic lymphadenectomy (PAL) in high-risk patients with endometrial cancer. Methods. We studied two groups of patients with endometrial cancer who underwent operation at Mayo Clinic (Rochester, MN) during the interval 1984 to 1993: (1) 137 patients at high risk for para- aortic lymph node involvement (myometrial invasion > 50%, palpable positive pelvic nodes, or positive adnexae), excluding stage IV disease, and (2) 51 patients with positive nodes (pelvic or para-aortic), excluding stage IV disease. By our definition, PAL required removal of five or more para-aortic nodes. Results. In both groups, no significant difference existed between patients who had PAL (PAL+) and those who did not (PAL-) in regard to clinical or pathologic variables, percentage irradiated, or surgical or radiation complications. Among the 137 high-risk patients, the 5-year progression-free survival was 62% and the 5-year overall survival was 71% for the PAL- group compared with 77 and 85%, respectively, for the PAL+ group (P = 0.12 and 0.06, respectively). For the 51 patients with positive nodes, the 5-year progression-free survival and 5-year overall survival for the PAL- group were 36 and 42% compared with 76 and 77% for the PAL+ group (P = 0.02 and 0.05, respectively). Lymph node recurrences were detected in 37% of the PAL-patients but in none of the PAL+ patients (P = 0.01). Multivariate analysis suggested that submission to PAL was a cogent predictor of progression-free survival (odds ratio = 0.25; P = 0.01) and overall survival (odds ratio = 0.23; P = 0.006). Conclusions. These results suggest a potential therapeutic role for formal PAL in endometrial cancer. (C) 2000 Academic Press.
AB - Objective. The aim of this study was to assess the potential therapeutic role of para-aortic lymphadenectomy (PAL) in high-risk patients with endometrial cancer. Methods. We studied two groups of patients with endometrial cancer who underwent operation at Mayo Clinic (Rochester, MN) during the interval 1984 to 1993: (1) 137 patients at high risk for para- aortic lymph node involvement (myometrial invasion > 50%, palpable positive pelvic nodes, or positive adnexae), excluding stage IV disease, and (2) 51 patients with positive nodes (pelvic or para-aortic), excluding stage IV disease. By our definition, PAL required removal of five or more para-aortic nodes. Results. In both groups, no significant difference existed between patients who had PAL (PAL+) and those who did not (PAL-) in regard to clinical or pathologic variables, percentage irradiated, or surgical or radiation complications. Among the 137 high-risk patients, the 5-year progression-free survival was 62% and the 5-year overall survival was 71% for the PAL- group compared with 77 and 85%, respectively, for the PAL+ group (P = 0.12 and 0.06, respectively). For the 51 patients with positive nodes, the 5-year progression-free survival and 5-year overall survival for the PAL- group were 36 and 42% compared with 76 and 77% for the PAL+ group (P = 0.02 and 0.05, respectively). Lymph node recurrences were detected in 37% of the PAL-patients but in none of the PAL+ patients (P = 0.01). Multivariate analysis suggested that submission to PAL was a cogent predictor of progression-free survival (odds ratio = 0.25; P = 0.01) and overall survival (odds ratio = 0.23; P = 0.006). Conclusions. These results suggest a potential therapeutic role for formal PAL in endometrial cancer. (C) 2000 Academic Press.
KW - Endometrial cancer
KW - Lymphadenectomy
KW - Management
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=0034012367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034012367&partnerID=8YFLogxK
U2 - 10.1006/gyno.1999.5688
DO - 10.1006/gyno.1999.5688
M3 - Article
C2 - 10684709
AN - SCOPUS:0034012367
SN - 0090-8258
VL - 76
SP - 348
EP - 356
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -